Enhanced Depletion Of Targeted Cells With Cd47 Blockade And An Immune Costimulatory Agonist
Patent No. EP3341015 (titled "Enhanced Depletion Of Targeted Cells With Cd47 Blockade And An Immune Costimulatory Agonist") was filed by The Board OF Trustees OF The Leland Stanford Junior University on Aug 26, 2016. The application was issued on Dec 27, 2023.
Patent Summary
A method for targeted cell depletion in cancer treatment, comprising administering a combination of agents that modulate immunoregulatory signaling pathways. The method includes blocking CD47 activity to prevent immune evasion by tumor cells, and simultaneously activating immune costimulatory molecules such as CD137 to enhance immune cell function. The combination of agents synergistically enhances targeted cell depletion, particularly in cancer treatment where tumor cells exploit immune evasion mechanisms to survive.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3341015
- Application Number
- EP16840215A
- Filing Date
- Aug 26, 2016
- Status
- Patent Maintained As Amended
- Nov 24, 2023
- Publication Date
- Dec 27, 2023
- External Links
- Slate, EP3341015B2, Google Patents